One of the quietest and most preventable problems in schizophrenia care is diabetes. It rarely makes the headlines, it doesn't show up on a relapse checklist, and yet it shortens lives more than almost any single psychiatric variable. Studies consistently show that people with schizophrenia develop type 2 diabetes at roughly two to three times the rate of the general population, and they often develop it earlier — sometimes within the first year of starting treatment.
Diabetes risk in schizophrenia is driven by a combination of antipsychotic medication, lifestyle factors, and the underlying illness itself — but consistent monitoring and a few practical changes can reduce that risk substantially.
How big is the gap?
Multiple large reviews put the prevalence of type 2 diabetes in schizophrenia at around 10–15% — compared with roughly 5–7% in the matched general population. A 2017 systematic review in World Psychiatry by Vancampfort and colleagues found a pooled prevalence of about 11.3% in people with schizophrenia, with rates rising sharply with age and length of treatment. The National Institute of Mental Health notes that metabolic conditions are a leading driver of the 10- to 20-year reduction in life expectancy associated with severe mental illness.
Why the risk is higher
1. The medications
Second-generation antipsychotics vary widely in metabolic risk. The American Diabetes Association/American Psychiatric Association consensus statement ranks them as follows:
- Highest risk: clozapine, olanzapine
- Moderate risk: quetiapine, risperidone, paliperidone
- Lower risk: aripiprazole, ziprasidone, lurasidone, brexpiprazole, lumateperone, cariprazine
Importantly, antipsychotics can raise blood sugar even before any weight gain occurs, by directly affecting insulin sensitivity in the muscles and liver.
2. The illness itself
Even drug-naïve, first-episode patients show a slightly higher rate of glucose dysregulation than matched controls. This suggests there is a shared biological vulnerability — possibly involving inflammation, HPA axis dysregulation, or genetic overlap between schizophrenia and metabolic disease.
3. Lifestyle
Negative symptoms reduce activity. Sedation makes exercise harder. Poverty, food insecurity, and a reliance on inexpensive ultra-processed food all increase the load. Smoking, which affects roughly 60% of people with schizophrenia, also worsens insulin resistance.
What monitoring should look like
The ADA/APA consensus recommends, at minimum:
- Baseline weight, waist, blood pressure, fasting glucose (or HbA1c), and a fasting lipid panel before starting an antipsychotic
- Re-check at 12 weeks
- Re-check at least annually thereafter
In real-world settings, fewer than half of patients receive this monitoring — a gap that families and patients can usefully push back on.
You notice excessive thirst, frequent urination, unexplained weight loss, blurred vision, or persistent fatigue. These can be early signs of diabetes that warrant urgent evaluation.
What actually helps
Switching antipsychotics
For some patients, switching from olanzapine or clozapine to a metabolically lighter agent (like aripiprazole or lurasidone) can reverse early metabolic changes. This is never trivial — switching carries relapse risk and should be done cautiously with a prescriber. See our guide on when to switch.
Metformin
Adding metformin to an antipsychotic regimen has reasonable evidence for both reducing weight gain and improving glucose control. A 2016 meta-analysis in JAMA Psychiatry by Mizuno and colleagues found that metformin produced an average weight loss of about 3 kg compared with placebo in patients on antipsychotics. For people who already have prediabetes, it is also an evidence-based diabetes preventive.
Lifestyle interventions designed for schizophrenia
Generic "eat better, move more" advice often fails in this population because it doesn't account for the cognitive and motivational barriers. Programs like the STRIDE trial and the InSHAPE program — group-based, peer-supported, schizophrenia-specific lifestyle programs — have shown clinically meaningful weight loss and improvements in metabolic markers. The principles are simple: small, repeatable changes; structured group support; and integration into routine care rather than a separate "fitness" silo.
Diet shifts that matter most
- Reducing sugary drinks (one of the highest-yield single changes)
- Building meals around protein and vegetables rather than ultra-processed carbohydrates
- A Mediterranean-style pattern has the most evidence for both metabolic and mental health benefits
Movement
Even 150 minutes a week of moderate activity (a brisk walk most days) measurably improves insulin sensitivity. See our exercise guide for ways to make this realistic when negative symptoms are heavy.
If diabetes has already developed
The treatment of diabetes in schizophrenia is the same as in anyone else — but the practical execution is harder. A few things that help:
- Coordinate care: a primary care provider and psychiatrist who actually communicate
- Simplify regimens: once-daily medications, pill organisers, and pharmacist follow-up
- Continuous glucose monitors are increasingly accessible and remove a lot of the guesswork
- Treat negative symptoms aggressively — they are often the biggest barrier to self-management
The bigger picture
The diabetes gap in schizophrenia is not inevitable. It is the product of medication choices, system failures, and lifestyle pressures that can each be addressed. Patients and families who push for baseline labs, regular re-checks, and an open conversation about metabolic risk consistently end up with better outcomes than those who don't. None of it is glamorous. All of it adds years to a life.
This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a qualified mental health professional. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.